Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1775 of 6351
-
Can a neck injection boost PTSD therapy? new trial aims to find out.
Symptom relief Recruiting nowThe goal of this clinical trial is to compare the combination of Massed Prolonged Exposure (PE); a behavioral therapy for PTSD) and a stellate ganglion block (SGB; an injection of a local anesthetic into the front of the neck) with Massed Prolonged Exposure and a sham injection i…
Phase 2 • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Symptom relief
Last updated Jun 26, 2026 13:42 UTC
-
New study aims to reduce brain fog after radiation for skull tumors
Knowledge-focused Recruiting nowCavernous sinus meningiomas are close to optic nerve, pituitary gland, cranial nerve, and hippocampi. The doses delivered to these structures are crucial and radiotherapy of cavernous sinus meningiomas exposes patients to late secondary effects (pituitary deficit, nerve palsy, c…
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
New scan could spare men with prostate cancer from unnecessary biopsies
Diagnosis Recruiting nowThis study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermediate-risk prostate cancer.
Sponsor: Weill Medical College of Cornell University • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
Can a crisis plan boost PTSD therapy and save lives?
Symptom relief Recruiting nowThe long-term goal of this study is to reduce suicidal thoughts and behaviors among treatment-seeking individuals who also have posttraumatic stress disorder (PTSD). Prolonged exposure (PE) and crisis response plan (CRP) have demonstrated empirical support for reducing suicide at…
Sponsor: Ohio State University • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Lung cancer treatment in hours, not weeks: new One-Day radiation trial shows promise
Disease control CompletedStereotactic body radiotherapy (SBRT) has become a standard of care for medically inoperable or high-risk operable early-stage non-small cell lung cancer (NSCLC) patients. It is also increasingly used to treat lung metastases in patients with oligometastatic disease. While SBRT i…
Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Can talking to an avatar help beat eating disorders?
Symptom relief CompletedThe Dialogue Study is a randomized, assessor-blinded parallel-groups superiority clinical trial fulfilling the CONSORT criteria for non-pharmacological treatment. The aim of the trial is to investigate the effect of a new virtual reality based psychotherapy for eating disorders. …
Sponsor: University Hospital Bispebjerg and Frederiksberg • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Custom 3D-printed masks aim to give kids with breathing problems a better night's sleep
Symptom relief OngoingNon-invasive ventilation (NIV) is the delivery of breathing support via a facemask. It is used to treat people whose natural breathing is ineffective. Evidence shows that, when used long-term, it improves both quality of life and life expectancy. Ventilation is delivered in the …
Sponsor: Sheffield Children's NHS Foundation Trust • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
New drug DNTH103 aims to tame muscle weakness in myasthenia gravis
Disease control OngoingThe purpose of this Phase 2 study is to evaluate the safety, tolerability, pharmacometrics, and efficacy of DNTH103 in participants with generalized myasthenia gravis (gMG).
Phase 2 • Sponsor: Dianthus Therapeutics • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New combo therapy aims to tackle Hard-to-Treat myeloma
Disease control Recruiting nowThe purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
Phase 1 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Could a simple pill replace IV drips for serious blood infections?
Disease control Recruiting nowThe Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of Gram-Negative BloodStream Infection (GN-BSI) is as effective…
Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New study tests 2-Year dupilumab treatment for Kids' eczema
Disease control OngoingThis is a 2-year, open-label, exploratory study with a 4-week screening period and a 104-week treatment phase designed to investigate dupilumab's long-term effect on skin barrier function as measured by transepidermal water loss (TEWL) before and after skin tape stripping (STS) i…
Phase 4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Super-Fine ultrasound could spare melanoma patients a second surgery
Diagnosis Stopped earlyCutaneous melanomas represent 4 to 11% of cutaneous cancers, but is responsible for 75% of the deaths reported for these pathologies. The incidence rate double every 10 years. Fourteen thousand cases and 1700 deaths were reported in France in 2015. The local staging of the cance…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail takes aim at Hard-to-Treat leukemia
Disease control Recruiting nowThe safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
Phase 1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Exercise may sharpen memory in breast cancer survivors
Symptom relief Recruiting nowThis phase II trial tests whether an exercise intervention works to improve cognitive function in breast cancer survivors. Many breast cancer survivors report cancer-related cognitive impairment, which this has recently become a priority in clinical research due to its dramatic i…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Could a weekly shot stop post-transplant weight gain?
Prevention Recruiting nowIn this study, semaglutide will be compared to placebo (a look-alike inactive substance, a "sugar pill") to determine if its use will prevent weight gain after liver transplantation (LT). In addition, researchers will be testing to determine if semaglutide prevents the developmen…
Phase 2 • Sponsor: University of Virginia • Aim: Prevention
Last updated Jun 27, 2026 13:03 UTC
-
New ultrasound device aims to speed up dialysis access healing
Disease control Recruiting nowThis is a prospective, multi-center, two-arm, randomized trial to quantify the performance of the EchoMark®/EchoSure® System for AVF diagnostic ultrasound when used under a protocol of biweekly use for assessing fistula maturation and reducing time to Clinical Maturation.
Sponsor: Sonavex, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Disease control Recruiting nowThis study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in subjects with relapsed or refractory CMML. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells…
Phase 1 • Sponsor: Huda Salman • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New Two-Drug HIV pill could match Three-Drug standard
Disease control OngoingThis study will compare safety, efficacy, participant reported outcomes and implementation outcomes of a fixed dose combination (FDC) of a two-drug regimen dolutegravir (DTG) plus lamivudine (3TC) and a three-drug regimen FDC of bictegravir (BIC), emtricitabine (FTC) and tenofovi…
Phase 3 • Sponsor: ViiV Healthcare • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can a phone app help latino kids eat better?
Prevention CompletedThe overall objective of this application is to pilot test an mHealth nutrition intervention within pediatric clinics serving Latino families and evaluate its potential for implementation. The investigators hypothesize the intervention will improve child diet quality and will be …
Sponsor: University of Kansas Medical Center • Aim: Prevention
Last updated Aug 29, 2026 00:00 UTC
-
Ultrasound zaps lung nerves to ease heart failure symptoms
Disease control By invitation onlyThis early feasibility study is intended to characterize the impact of pulmonary artery denervation on the quality of life in Heart Failure Patients with Group 2 Pulmonary Hypertension
Sponsor: Gradient Denervation Technologies • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC